News Releases | Merck Newsroom Home

By Date
By Category
Consumer Care News
Vaccine News
Research and Development News
Corporate News
Financial News
Corporate Responsibility News

By Date

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
5/23/13 5:00 pm EDT
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
5/22/13 6:28 pm EDT
Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
5/17/13 8:30 am EDT
Merck Prices $ 6.5 Billion Debt Offering
5/15/13 6:29 pm EDT
Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth
5/14/13 4:23 pm EDT
Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference
5/14/13 9:15 am EDT
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to Developing Countries through UNICEF Tender
5/9/13 7:20 am EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
5/8/13 8:30 am EDT
Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management
5/7/13 10:33 am EDT
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
5/3/13 3:06 pm EDT
Merck Announces First-Quarter 2013 Financial Results
5/1/13 7:00 am EDT
Supplemental_Earnings_Package_1Q13.pdf (189.7 KB)
Merck Announces New $15 Billion Share Repurchase Program
5/1/13 6:58 am EDT
Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
4/29/13 5:00 pm EDT
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
4/29/13 7:30 am EDT
Merck Named a Top 50 Company for Diversity by DiversityInc
4/24/13 4:43 pm EDT
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
4/24/13 7:30 am EDT
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
4/23/13 6:39 am EDT
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
4/22/13 7:30 am EDT
Merck Opens New Manufacturing Facility in Hangzhou, China
4/16/13 8:00 am EDT
Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole)
4/10/13 8:30 am EDT
Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
4/8/13 10:37 am EDT
Merck to Hold First-Quarter 2013 Sales and Earnings Conference Call on May 1
4/1/13 8:30 am EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
3/27/13 8:00 am EDT
Mistrial Declared in FOSAMAX® (alendronate sodium) New Jersey State Court Trial
3/18/13 2:07 pm EDT
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease
3/13/13 8:30 am EDT
Merck Provides Update on IMPROVE-IT Trial
3/12/13 8:00 am EDT
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial
3/11/13 9:30 am EDT
Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
3/9/13 12:50 pm EST
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
3/7/13 7:30 am EST
Merck Receives 2013 ENERGY STAR Sustained Excellence Award
3/6/13 8:30 am EST
Merck to Present at the 33rd Annual Cowen Health Care Conference
3/5/13 8:30 am EST
Merck Scientist Daria Hazuda Presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
3/4/13 9:59 am EST
Bruce Kuhlik and Merck Honored by PBI for Commitment to Pro Bono
2/28/13 9:43 am EST
Merck Announces Second-Quarter 2013 Dividend
2/26/13 2:29 pm EST
Merck to Present at the Citi 2013 Global Healthcare Conference
2/26/13 8:30 am EST
Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets
2/22/13 8:30 am EST
Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
2/20/13 7:00 am EST
Merck Resolves Securities Class-Action Lawsuits Related to the ENHANCE Trial
2/14/13 8:00 am EST
Merck Statement on Venezuelan Currency Devaluation
2/13/13 9:00 am EST
Merck to Present at the Leerink Swann 2013 Global Healthcare Conference
2/12/13 8:30 am EST
Renowned Photographer and HIV Activist Duane Cramer Partners with Project Runway Star Mondo Guerra and Merck on I Design Campaign
2/7/13 9:04 am EST
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
2/1/13 7:00 am EST
Supplemental_Earnings_Package_4Q12.pdf (440.15 KB)
FDA Approves OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
1/25/13 11:30 am EST
Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)
1/11/13 7:39 am EST
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
1/7/13 8:00 am EST
Merck to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/4/13 8:30 am EST
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets
1/2/13 4:45 pm EST
Merck to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
1/2/13 8:30 am EST
Merck Announces Fourth-Quarter 2012 Sales and Earnings Conference Call
1/2/13 8:00 am EST
Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint
12/20/12 8:30 am EST
Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program
12/18/12 7:30 am EST
The JAMA Network and Merck Announce Strategic Collaboration
12/3/12 10:40 am EST
Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease
12/3/12 6:30 am EST
Merck Launches Maternal Health Awareness Campaign, Once Upon a Birth, with Actress Melissa Joan Hart
11/29/12 9:02 am EST
Merck Provides Update on EU Marketing Authorization Application for Ridaforolimus
11/29/12 8:00 am EST
Mondo Guerra of Project Runway All Stars Unveils One-of-a-Kind Clothing Design in Honor of World AIDS Day
11/28/12 10:35 am EST
Merck Increases Quarterly Dividend
11/27/12 2:57 pm EST
Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer
11/27/12 8:30 am EST
Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma
11/11/12 2:00 pm EST
Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients
11/10/12 9:00 am EST
Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
11/10/12 9:00 am EST
Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine
11/8/12 8:30 am EST
Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration
11/8/12 8:00 am EST
Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus
11/2/12 2:00 pm EDT
Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx
11/1/12 6:00 pm EDT
Merck Announces Third-Quarter 2012 Financial Results
10/26/12 7:00 am EDT
Supplemental_Earnings_Package_3Q12.pdf (586.49 KB)
Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation
10/23/12 2:15 pm EDT
VICTRELIS® (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent
10/17/12 7:30 am EDT
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
10/15/12 3:00 am EDT
Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck’s Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis
10/13/12 12:15 pm EDT
On World Sight Day, Merck and Partners Mark 25 Years of Successful Collaboration To Help Eliminate River Blindness
10/11/12 8:00 am EDT
Merck to Move Global Headquarters Within New Jersey
10/9/12 8:10 am EDT
Phase IIb Data Showed Merck’s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
10/3/12 8:46 am EDT
Merck to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at The American Association for the Study of Liver Diseases 2012 Annual Meeting
10/1/12 11:12 am EDT
Merck to Hold Third-Quarter 2012 Sales and Earnings Conference Call on October 26
9/26/12 8:00 am EDT
Merck to Present at the UBS Global Life Sciences Conference
9/19/12 8:00 am EDT
Merck Announces Continued Commitment to Global Responsibility
9/13/12 8:08 am EDT
Merck Highlights Ongoing Commitment to Developing Medicines Targeting Infectious Disease at 52nd Annual ICAAC
9/12/12 8:08 am EDT
Merck Prices $2.5 Billion Debt Offering
9/10/12 7:00 pm EDT
Merck Announces New Phase III Data for Suvorexant, an Investigational Insomnia Medicine
9/10/12 8:30 am EDT
Merck to Present at Morgan Stanley Global Healthcare Conference
9/10/12 8:00 am EDT
Republic of Uganda and Merck Launch Cervical Cancer Vaccination Program
9/4/12 8:08 am EDT
Merck Provides Update on Cardiovascular Development Programs
8/26/12 8:00 am EDT
Merck Announces Second-Quarter 2012 Financial Results
7/27/12 7:00 am EDT
Supplemental_Earnings_Package_2Q12.pdf (343.9 KB)
Merck Recognizes World Hepatitis Day with Partnerships and Grants to Support Global and U.S. Hepatitis C Communities
7/26/12 8:08 am EDT
Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body
7/25/12 5:00 pm EDT
Merck Announces Fourth-Quarter 2012 Dividend
7/24/12 12:34 pm EDT
Merck Signs Two Deals for Novel HIV Drug Candidates and Initiates Phase II Clinical Trial of MK-1439 for HIV
7/24/12 8:00 am EDT
ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks
7/22/12 3:00 pm EDT
Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
7/19/12 8:08 am EDT
Fashion Designer and Project Runway All Stars Winner Mondo Guerra Collaborates with Merck to Help Empower People with HIV to Work with Their Doctors to "Tailor" Their Treatment Plan
7/17/12 9:00 am EDT
Merck Launches Richard T. Clark Fellowship Program with PSI Partnership
7/17/12 8:08 am EDT
Merck Highlights Data Presentations at the Alzheimer’s Association International Conference, 2012
7/13/12 5:00 pm EDT
Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis
7/11/12 5:12 pm EDT
Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning
7/11/12 10:15 am EDT
Merck to Hold Second-Quarter 2012 Sales and Earnings Conference Call on July 27
6/27/12 8:00 am EDT
Merck and AstraZeneca Agree to Amend Partnership
6/27/12 7:00 am EDT
Merck Statement on CDC Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults
6/20/12 1:23 pm EDT
Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery
6/18/12 8:30 am EDT
Merck to Present at Wells Fargo Securities Research and Economics 2012 Health Care Conference
6/18/12 8:00 am EDT
U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit
6/15/12 5:05 pm EDT
New Partnership With U.S. and Norwegian Governments and the Private Sector Formed to Save the Lives of Mothers and Their Newborn Children
6/14/12 8:08 am EDT
New Phase III Data Showed Merck’s Investigational Insomnia Medicine Suvorexant Improved Patients' Ability to Fall Asleep and Stay Asleep
6/13/12 8:00 am EDT
Merck Receives Complete Response Letter from U.S. Food and Drug Administration for Investigational Medicine Ridaforolimus
6/5/12 4:35 pm EDT
Merck to Present at Jefferies 2012 Global Healthcare Conference
6/1/12 8:00 am EDT
Merck to Present at Sanford C. Bernstein 28th Strategic Decisions Conference
5/30/12 8:00 am EDT
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus
5/25/12 7:18 am EDT
Merck Announces Third-Quarter 2012 Dividend
5/22/12 12:50 pm EDT
FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1
5/21/12 8:00 am EDT
Merck to Present at Bank of America Merrill Lynch 2012 Healthcare Conference
5/16/12 8:00 am EDT
Dr. Scholl's® Survey Reveals America is on the Move When Foot Pain Doesn't Get in the Way
5/10/12 9:08 am EDT
Merck to Present at Deutsche Bank 37th Annual Health Care Conference
5/8/12 8:00 am EDT
COPPERTONE® Launches Nationwide Contest in Search of Modern Little Miss Coppertone
5/3/12 8:08 am EDT
Merck Wins U.S. ZETIA® (ezetimibe)/ VYTORIN® (ezetimibe/simvastatin) Patent Infringement Lawsuit
4/27/12 6:05 pm EDT
Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology
4/27/12 8:08 am EDT
Merck Announces First-Quarter 2012 Financial Results
4/27/12 7:00 am EDT
Merck_Supplemental_Earnings_Package_1Q12.pdf (279.09 KB)
Opportunity’s Knocking – Are Young Adult Women Prepared?
4/26/12 8:08 am EDT
Merck Named as Leader in Maplecroft Climate Innovation Index
4/24/12 8:08 am EDT
Merck and RESOLVE Remind Couples That a Conversation with a Specialist Could Be The Start of Something Small
4/23/12 8:08 am EDT
Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy
4/19/12 7:00 am EDT
Merck Wins Another FOSAMAX® (alendronate sodium) State Court Trial
4/18/12 3:42 pm EDT
Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)
4/16/12 7:06 am EDT
New Data Analyses for VICTRELIS™ (boceprevir) Will Be Presented at The International Liver Congress™ / 2012 EASL Annual Meeting
4/4/12 8:08 am EDT
Randy Jackson Partners with Merck to Urge People with Type 2 Diabetes to Take Their Diabetes to Heart
4/3/12 8:08 am EDT
Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
4/2/12 9:04 am EDT
Merck Appoints Michael J. Holston as Chief Ethics and Compliance Officer
3/28/12 9:30 am EDT
Merck to Hold First-Quarter 2012 Sales and Earnings Conference Call on April 27
3/27/12 8:00 am EDT
In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
3/24/12 9:10 am EDT
Merck and Safe Water Network Launch Initiative to Improve Water Access and Help Reduce the Impact of Water-Borne Disease in India
3/20/12 8:08 am EDT
Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)
3/15/12 8:00 am EDT
Merck to Present at the Barclays Capital 2012 Global Healthcare Conference
3/13/12 8:00 am EDT
Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1
3/6/12 8:14 pm EST
Merck Confirms 2012 Full-Year Guidance
3/6/12 8:00 am EST
Merck’s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
3/5/12 8:30 am EST
Merck Receives 2012 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
3/5/12 8:08 am EST
Merck to Present at the Cowen & Company 32nd Annual Health Care Conference
3/5/12 8:00 am EST
Merck Announces Second-Quarter 2012 Dividend
2/28/12 1:36 pm EST
Merck to Present at the 2012 Citi Global Healthcare Conference
2/28/12 8:30 am EST
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey
2/27/12 8:08 am EST
Singer Jon Secada Joins Merck and American Liver Foundation's 'Tune In to Hep C' Public Awareness Campaign
2/16/12 8:08 am EST
Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil
2/15/12 7:00 am EST
Merck to Present at the Leerink Swann 2012 Global Healthcare Conference
2/14/12 8:30 am EST
FDA Approves ZIOPTAN™ (tafluprost ophthalmic solution), Merck’s Once-Daily, Preservative-Free Ophthalmic Medication
2/13/12 10:15 am EST
Kentucky Court Of Appeals Reverses Certification of a Class of Plaintiffs Seeking Reimbursement for Vioxx® Costs
2/10/12 8:08 am EST
Thomas E. Shenk To Retire From Merck's Board of Directors
2/8/12 3:00 pm EST
Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors
2/8/12 8:08 am EST
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
2/7/12 8:30 am EST
The NAMES Project Foundation and Merck Launch "Call My Name" National Tour AIDS Panel Making Workshop to Focus Attention on HIV/AIDS Crisis in African American Communities
2/7/12 8:08 am EST
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
2/6/12 8:45 am EST
FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
2/2/12 2:44 pm EST
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
2/2/12 7:00 am EST
MRK_Supplemental_Earnings_Package_4Q11.pdf (353.15 KB)
Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2
1/26/12 8:00 am EST
New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
1/25/12 8:30 am EST
Merck Resolves Vioxx® Litigation in Canada
1/19/12 8:08 am EST
Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference
1/9/12 8:30 am EST
FDA Approves Merck’s ISENTRESS® (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy
1/6/12 8:08 am EST
Merck to Present at Goldman Sachs 2012 Healthcare Event
1/4/12 8:30 am EST
Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV
12/21/11 11:19 am EST
Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection
12/15/11 8:08 am EST
Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting
12/12/11 8:08 am EST
Merck Establishes New MSD R&D Asia Headquarters
12/6/11 1:30 am EST
Merck for Mothers and PATH Collaborate to Identify Innovations that Save Mothers' Lives
12/5/11 8:08 am EST
Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney’s Office for the District of Massachusetts Related to Vioxx®
11/22/11 3:23 pm EST
Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM
11/13/11 8:05 am EST
Merck and Partners Make Progress In Long-Term Commitment to End River Blindness
11/11/11 8:08 am EST
Merck to Present at the 2011 Credit Suisse Healthcare Conference
11/10/11 5:00 pm EST
Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing
11/10/11 9:55 am EST
Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth
11/10/11 8:55 am EST
Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
11/9/11 9:00 am EST
Interim Data for Merck's VICTRELISTM (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
11/5/11 9:00 am EDT
FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease
11/2/11 5:36 pm EDT
Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report
10/31/11 4:30 pm EDT
Merck Announces Third Quarter 2011 Financial Results
10/28/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_3Q11.pdf (321.35 KB)
New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
10/26/11 5:35 pm EDT
CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
10/25/11 2:17 pm EDT
Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/24/11 4:30 pm EDT
Interim Phase IIb Data for Merck's VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting
10/20/11 8:00 am EDT
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
10/13/11 8:00 am EDT
FDA Approves Merck’s JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease
10/7/11 7:53 pm EDT
Merck Announces Retirement of Chairman and Former CEO Richard T. Clark
10/6/11 11:15 am EDT
FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor
10/5/11 7:35 am EDT
Merck Adds New Medication Adherence Resources to Consumer Web Site
10/4/11 8:00 am EDT
Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium)
10/3/11 11:54 am EDT
Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
9/30/11 10:55 am EDT
Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28
9/30/11 8:00 am EDT
Merck Publishes 2010 Global Corporate Responsibility Report
9/30/11 8:00 am EDT
Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
9/28/11 4:10 pm EDT
Merck Names Cuong Viet Do as Chief Strategy Officer
9/27/11 8:30 am EDT
Study of ZOLINZA® (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint
9/23/11 8:00 am EDT
Merck Joins Global Fight to Help Save Women's Lives During Pregnancy and Childbirth
9/20/11 8:00 am EDT
New Data on Odanacatib, Merck’s Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research
9/19/11 5:40 pm EDT
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race
9/19/11 8:00 am EDT
Merck to Present at Bank of America Merrill Lynch Global Healthcare Conference
9/14/11 8:00 am EDT
Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations
9/13/11 9:03 am EDT
Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies
9/13/11 12:05 am EDT
Merck to Present at Morgan Stanley Global Healthcare Conference
9/12/11 8:00 am EDT
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial
9/7/11 8:08 am EDT
Texas Supreme Court Finds for Merck in VIOXX® Case
8/26/11 8:08 am EDT
Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health
8/23/11 8:00 am EDT
Merck Announces Second Quarter 2011 Financial Results
7/29/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_2Q11.pdf (378.1 KB)
Merck Recognizes World Hepatitis Day With Partnerships and Grants to Support Global Hepatitis C Community
7/28/11 8:08 am EDT
Latest Merck Manual Delivers Trusted Health Care Information in Print and Electronic Formats
7/27/11 8:08 am EDT
Merck Announces Fourth Quarter 2011 Dividend
7/26/11 1:44 pm EDT
R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and The American Liver Foundation to Turn Up the Volume Around Hep C
7/26/11 8:08 am EDT
Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture
7/21/11 6:00 pm EDT
Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C
7/20/11 7:00 am EDT
Merck to Hold Second-Quarter 2011 Sales and Earnings Conference Call on July 29
6/30/11 8:00 am EDT
Merck Announces New Name for its Animal Health Division
6/29/11 8:08 am EDT
UPS and Merck Expand Their Distribution and Logistics Agreement
6/28/11 7:00 am EDT
Legendary Musician Gregg Allman Joins Merck and American Liver Foundation to Launch Tune In to Hep C Public Awareness Campaign
6/21/11 8:08 am EDT
Actress JoAnna Garcia Swisher "Goes There" in a New Campaign with Merck to Motivate Women to "Get Real" When Talking to Their Physicians about Their Health
6/8/11 8:08 am EDT
Merck to Present at Goldman Sachs 32nd Annual Healthcare Conference
6/7/11 8:00 am EDT
Roche and Merck Collaborate to Develop Diagnostic Tests for Merck’s Investigational Cancer Therapies
6/7/11 7:30 am EDT
Merck Commends GAVI Alliance on Continued Efforts to Improve Access
6/5/11 8:08 am EDT
Merck Signs on to United Nations CEO Water Mandate
6/2/11 8:08 am EDT
Merck to Present at Sanford Bernstein 27th Strategic Decisions Conference
5/31/11 8:00 am EDT
Merck Announces Third Quarter 2011 Dividend
5/24/11 11:24 am EDT
Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C
5/17/11 11:30 am EDT
Merck Completes Acquisition of Inspire Pharmaceuticals, Inc.
5/16/11 11:30 am EDT
Merck Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered
5/13/11 8:30 am EDT
Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus
5/9/11 8:30 am EDT
Merck to Present at Deutsche Bank 36th Annual Healthcare Conference
5/2/11 8:00 am EDT
Merck Announces First Quarter 2011 Financial Results
4/29/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_1Q11.pdf (291.63 KB)
Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire
4/28/11 8:30 am EDT
Merck Announces New $5 Billion Share Repurchase Program
4/27/11 7:45 am EDT
Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
4/15/11 9:01 am EDT
Merck Reaffirms 2011 Non-GAAP EPS Target
4/15/11 7:01 am EDT
Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®
4/15/11 7:00 am EDT
Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets
4/11/11 8:01 am EDT
Merck to Acquire Inspire Pharmaceuticals, Inc.
4/5/11 9:30 am EDT
Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on April 29
4/1/11 1:00 pm EDT
Jury Finds for Merck and Other Defendants on the Key Issue in an Environmental Contamination Lawsuit
3/31/11 8:08 am EDT
Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health
3/22/11 2:00 am EDT
Merck Receives 2011 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
3/16/11 8:08 am EDT
Merck to Present at Barclays Capital 2011 Global Healthcare Conference
3/15/11 8:00 am EDT
SisterLove, Inc. and Merck Launch "Everyone Has A Story" Series
3/10/11 8:08 am EST
Merck to Present at Cowen and Company's 31st Annual Health Care Conference
3/7/11 8:00 am EST
Merck to Present at Citi 2011 Global Health Care Conference
2/28/11 2:00 pm EST
Fujifilm to Acquire Merck Biomanufacturing Network
2/28/11 12:01 am EST
Merck Announces Second Quarter 2011 Dividend
2/22/11 3:54 pm EST
Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial
2/14/11 11:07 am EST
Merck Announces Fourth Quarter and Full Year 2010 Financial Results
2/3/11 7:00 am EST
John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age
1/25/11 4:23 pm EST
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey State Court
1/18/11 8:08 am EST
Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates
1/12/11 7:30 am EST
Merck to Present at the 29th Annual J.P. Morgan Healthcare Conference
1/11/11 8:00 am EST
Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3
1/4/11 7:11 pm EST
Merck Prices $2.0 Billion Debt Offering
12/7/10 5:14 pm EST
Merck to Acquire SmartCells, Inc.
12/2/10 7:41 am EST
Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T. Clark to Continue as Chairman
11/30/10 7:00 am EST
Merck Announces First-Quarter 2011 Dividend
11/23/10 3:29 pm EST
Merck Wins Another Federal FOSAMAX® (alendronate sodium) Bellwether Trial
11/19/10 5:56 pm EST
Merck and Partners Make Progress in Long-Term Commitment to End River Blindness
11/11/10 8:30 am EST
Merck Wins TEMODAR® Patent Infringement Lawsuit on Appeal
11/9/10 2:46 pm EST
Merck Announces Third-Quarter 2010 Financial Results
10/29/10 7:00 am EDT
3Q10_Supplemental_Earnings_Package.pdf (370.44 KB)
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
10/28/10 8:08 am EDT
Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach
10/13/10 8:08 am EDT
Tenth Edition of The Merck Veterinary Manual Debuts
10/13/10 8:08 am EDT
Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan
10/12/10 5:00 am EDT
Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX® (alendronate sodium) Case
10/4/10 4:10 pm EDT
Merck to Hold Third-Quarter 2010 Sales and Earnings Conference Call on Oct. 29
10/1/10 8:30 am EDT
Merck to Appeal Verdict in Massachusetts Medicaid Case
9/30/10 4:05 pm EDT
Why So Shy? What Females of the Facebook Generation Are Not Sharing in the OB/GYN Office that Could Affect Their Health
9/29/10 8:08 am EDT
Merck Significantly Expands its Patient Assistance Program Offerings to Provide Access to More Medicines for People in Need
9/22/10 8:30 am EDT
Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign
9/16/10 8:30 am EDT

By Category

More Prescription Medicine News

Consumer Care News

Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management
5/7/13 10:33 am EDT
FDA Approves OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
1/25/13 11:30 am EST
Dr. Scholl's® Survey Reveals America is on the Move When Foot Pain Doesn't Get in the Way
5/10/12 9:08 am EDT
COPPERTONE® Launches Nationwide Contest in Search of Modern Little Miss Coppertone
5/3/12 8:08 am EDT

More Consumer Care News

Vaccine News

More Vaccine News

Research and Development News

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
5/23/13 5:00 pm EDT
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
5/22/13 6:28 pm EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
5/8/13 8:30 am EDT
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
5/3/13 3:06 pm EDT

More Research & Development News

Corporate News

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
5/23/13 5:00 pm EDT
Merck Statement on FDA Advisory Committee Meeting for Suvorexant
5/22/13 6:28 pm EDT
Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT

More Corporate News

Financial News

Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT
Merck Prices $ 6.5 Billion Debt Offering
5/15/13 6:29 pm EDT
Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference
5/14/13 9:15 am EDT

More Financial News

Corporate Responsibility News

Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
5/17/13 8:30 am EDT
Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth
5/14/13 4:23 pm EDT
Bruce Kuhlik and Merck Honored by PBI for Commitment to Pro Bono
2/28/13 9:43 am EST
Renowned Photographer and HIV Activist Duane Cramer Partners with Project Runway Star Mondo Guerra and Merck on I Design Campaign
2/7/13 9:04 am EST

More Corporate Responsibility News

The information contained in each news release posted on this page was factually accurate on the date it was issued. The company assumes no duty to update the information to reflect subsequent developments. Readers of the news releases should not rely upon the information as current or accurate after their issuance dates.